YAKHAK HOEJI (약학회지)

The Pharmaceutical Society of Korea (대한약학회)
권호 표지
DOI QR코드

DOI QR Code

Novel Lead Optimization Strategy Using Quantitative Structure-Activity Relationship and Physiologically-Based Pharmacokinetics Modeling

정량적 구조-활성 상관 관계와 생리학 기반 약물동태를 사용한 새로운 선도물질 최적화 전략

  • Received : 2015.04.05
  • Accepted : 2015.07.31
  • Published : 2015.08.30
Download PDF
⟨ Previous Next ⟩

Abstract

The purpose of this study is to demonstrate how lead compounds are best optimized with the application of in silico QSAR and PBPK modeling at the early drug discovery stage. Several predictive QSAR models such as $IC_{50}$ potency model, intrinsic clearance model and brain penetration model were built and applied to a set of virtually synthesized library of the BACE1 inhibitors. Selected candidate compounds were also applied to the PBPK modeling for comparison between the predicted animal pharmacokinetic parameters and the observed ones in vivo. This novel lead optimization strategy using QSAR and PBPK modelings could be helpful to expedite the drug discovery process.

Keywords

References

  1. Wenlock, M. C., Austin, R. P., Barton, P., Davis, A. M. and Leeson, P. D. : A comparison of physiochemical property profiles of development and marketed oral drugs. J. Med. Chem. 46, 1250 (2003). https://doi.org/10.1021/jm021053p
  2. Gleeson, M. P., Hersey, A., Montanari, D. and Overington, J. : Probing the links between in vitro potency, ADMET and physicochemical parameters. Nat. Rev. Drug Discov. 10, 197 (2011). https://doi.org/10.1038/nrd3367
  3. Kenny, J. R. : Predictive DMPK: in silico ADME predictions in drug discovery. Mol. Pharm. 10, 1151 (2013). https://doi.org/10.1021/mp400102t
  4. U.S. Food and drug administration, http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm292923.pdf.
  5. Jones, H. and Rowland-Yeo, K. : Basic concepts in physiologically based pharmacokinetic modeling in drug discovery and development. CPT Pharmacometrics Syst. Pharmacol. 2, e63 (2013). https://doi.org/10.1038/psp.2013.41
  6. Grime, K. H., Barton, P. and McGinnity, D. F. : Application of in silico, in vitro and preclinical pharmacokinetic data for the effective and efficient prediction of human pharmacokinetics. Mol. Pharm. 10, 1191 (2013). https://doi.org/10.1021/mp300476z
  7. Ortwine, D. F. and Aliagas, I. : Physicochemical and DMPK in silico models: facilitating their use by medicinal chemists. Mol. Pharm. 10, 1153 (2013). https://doi.org/10.1021/mp3006193
  8. Hosea, N. A. and Jones, H. M. : Predicting pharmacokinetic profiles using in silico derived parameters. Mol. Pharm. 10, 1207 (2013). https://doi.org/10.1021/mp300482w
  9. Rueeger, H., Lueoend, R., Rogel, O., Rondeau, J. M., Mobitz, H., Machauer, R., Jacobson, L., Staufenbiel, M., Desrayaud, S. and Neumann, U. : Discovery of cyclic sulfone hydroxyethylamines as potent and selective beta-site APPcleaving enzyme 1 (BACE1) inhibitors : structure-based design and in vivo reduction of amyloid beta-peptides. J. Med. Chem. 55, 3364 (2012). https://doi.org/10.1021/jm300069y
  10. 의약화학 편집위원회 : 의약화학, 개정판, 신일북스, 서울 p. 47 (2011).
  11. Wager, T. T., Hou, X., Verhoest, P. R. and Villalobos, A. : Moving beyond rules: the development of a central nervous system multiparameter optimization (CNS MPO) approach to enable alignment of druglike properties. ACS Chem. Neurosci. 1, 435 (2010). https://doi.org/10.1021/cn100008c
  12. Rowland, M., Peck, C. and Tucker, G. : Physiologically-based pharmacokinetics in drug development and regulatory science. Annu. Rev. Pharmacol. Toxicol. 51, 45 (2011). https://doi.org/10.1146/annurev-pharmtox-010510-100540
  13. Khalil, F. and Laer, S. : Physiologically based pharmacokinetic models in the prediction of oral drug exposure over the entire pediatric age range-sotalol as a model drug. AAPS J. 16, 226 (2014). https://doi.org/10.1208/s12248-013-9555-6
  14. Maharaj, A., Barrett, J. and Edginton, A. : A workflow example of PBPK modeling to support pediatric research and development : case study with lorazepam. AAPS J. 15, 455 (2013). https://doi.org/10.1208/s12248-013-9451-0
  15. Yusof, I., Shah, F., Hashimoto, T., Segall, M. D. and Greene, N. : Finding the rules for successful drug optimisation. Drug Discov. Today 19, 680 (2014). https://doi.org/10.1016/j.drudis.2014.01.005
  16. U.S. Food and drug administration, http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/205552s002lbl.pdf.

Cited by

  1. 신약 후보물질 발굴을 위한 비임상포뮬레이션 전략 vol.62, pp.3, 2015, https://doi.org/10.17480/psk.2018.62.3.179